JR-441 + JR-441 + JR-441
Phase 1/2Active 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis III-A
Conditions
Mucopolysaccharidosis III-A
Trial Timeline
Oct 4, 2023 → Oct 31, 2029
NCT ID
NCT06095388About JR-441 + JR-441 + JR-441
JR-441 + JR-441 + JR-441 is a phase 1/2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis III-A. The current trial status is active. This product is registered under clinical trial identifier NCT06095388. Target conditions include Mucopolysaccharidosis III-A.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06095388 | Phase 1/2 | Active |
Competing Products
20 competing products in Mucopolysaccharidosis III-A